• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by agilon health inc.

    2/13/24 4:58:51 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AGL alert in real time by email
    SC 13G 1 tv0204-agilonhealthinc.htm SCHEDULE 13G agilonhealthinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  agilon health Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  00857U107

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  00857U107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    125,960

    7.  SOLE DISPOSITIVE POWER

    28,134,314

    8.  SHARED DISPOSITIVE POWER

    441,947

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,576,261

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.04%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    agilon health Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    6210 East Highway 290, Suite 450
    Austin, TX 78723

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    00857U107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $AGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGL

    DatePrice TargetRatingAnalyst
    4/25/2025$5.00Neutral → Buy
    Citigroup
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    1/10/2025Hold
    Needham
    12/16/2024Neutral
    Macquarie
    12/11/2024$2.50Mkt Perform
    Bernstein
    11/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    11/8/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $AGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • agilon health to Participate in Bernstein's 41st Annual Strategic Decisions Conference

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the Bernstein 41st Annual Strategic Decisions Conference including a fireside chat presentation on Wednesday, May 28 at 4:30 PM Eastern Time. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering

      5/19/25 4:04:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health to Participate in BofA Securities 2025 Health Care Conference

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the BofA Securities 2025 Health Care Conference including a fireside chat presentation on Wednesday, May 14 at 1:00 PM Eastern Time. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physicia

      4/4/25 4:15:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Sets Date to Report First Quarter 2025 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

      3/25/25 4:05:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/13/24 12:49:26 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/8/24 10:52:39 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/6/24 4:47:14 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Financials

    Live finance-specific insights

    See more
    • agilon health Sets Date to Report First Quarter 2025 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

      3/25/25 4:05:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Tuesday February 25, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 599648. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A

      2/10/25 4:01:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Reports Third Quarter 2024 Results

      Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c

      11/7/24 4:00:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 9,331 shares, decreasing direct ownership by 0.83% to 1,121,221 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 8:11:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Director Mckenzie Diana was granted 78,724 shares, increasing direct ownership by 134% to 137,543 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 7:39:34 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Director Wulf John William was granted 78,724 shares, increasing direct ownership by 38% to 284,857 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 6:32:44 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agilon Health upgraded by Citigroup with a new price target

      Citigroup upgraded Agilon Health from Neutral to Buy and set a new price target of $5.00

      4/25/25 8:23:09 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Agilon Health upgraded by Bernstein with a new price target

      Bernstein upgraded Agilon Health from Mkt Perform to Outperform and set a new price target of $8.50

      4/8/25 9:06:22 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Agilon Health upgraded by Citigroup with a new price target

      Citigroup upgraded Agilon Health from Sell to Neutral and set a new price target of $2.25 from $1.75 previously

      1/10/25 7:25:30 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

      4/A - agilon health, inc. (0001831097) (Issuer)

      4/3/25 7:40:25 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      3/18/25 6:42:37 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Chief Markets Officer Shaker Benjamin bought 11,786 shares and covered exercise/tax liability with 4,143 shares, increasing direct ownership by 2% to 457,058 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      3/18/25 6:41:48 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    SEC Filings

    See more
    • agilon health inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - agilon health, inc. (0001831097) (Filer)

      5/30/25 4:43:53 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

      SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

      5/13/25 11:44:13 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

      SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

      5/12/25 10:44:45 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Leadership Updates

    Live Leadership Updates

    See more
    • agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

      Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

      7/10/24 8:00:00 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Names Jeff Schwaneke New Chief Financial Officer

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

      6/5/24 8:00:00 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health, inc. investors: Please contact the Portnoy Law Firm to recover your losses; May 28, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises agilon health, inc. (NYSE:AGL) investors that a lawsuit was filed on behalf of investors that purchased agilon securities between April 15, 2021 and February 27, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to

      5/13/24 6:31:12 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care